JP2017533194A5 - - Google Patents

Info

Publication number

JP2017533194A5

JP2017533194A5 JP2017519922A JP2017519922A JP2017533194A5 JP 2017533194 A5 JP2017533194 A5 JP 2017533194A5 JP 2017519922 A JP2017519922 A JP 2017519922A JP 2017519922 A JP2017519922 A JP 2017519922A JP 2017533194 A5 JP2017533194 A5 JP 2017533194A5

Authority

JP

Japan

Prior art keywords

amino acid

terminal region

sequence

peptide

seq

Prior art date

2015-10-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 143
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 130
• 210000004897 n-terminal region Anatomy 0.000 claims description 110
• 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 85
• 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 claims description 85
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 82
• 150000001413 amino acids Chemical class 0.000 claims description 64
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
• 210000004899 c-terminal region Anatomy 0.000 claims description 52
• 125000000539 amino acid group Chemical group 0.000 claims description 43
• 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 42
• 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 42
• 206010028980 Neoplasm Diseases 0.000 claims description 40
• 239000000203 mixture Substances 0.000 claims description 35
• 208000035475 disorder Diseases 0.000 claims description 33
• 201000010099 disease Diseases 0.000 claims description 27
• 229920001213 Polysorbate 20 Polymers 0.000 claims description 25
• 239000007983 Tris buffer Substances 0.000 claims description 25
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 25
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 25
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 24
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 23
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 23
• 238000006467 substitution reaction Methods 0.000 claims description 23
• 229940074410 trehalose Drugs 0.000 claims description 23
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
• 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 19
• 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 claims description 19
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 19
• 238000012217 deletion Methods 0.000 claims description 19
• 230000037430 deletion Effects 0.000 claims description 19
• 201000011510 cancer Diseases 0.000 claims description 17
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
• 239000003613 bile acid Substances 0.000 claims description 10
• 230000003247 decreasing effect Effects 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 9
• 239000012634 fragment Substances 0.000 claims description 9
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 9
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 9
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
• 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 8
• 238000009472 formulation Methods 0.000 claims description 8
• 239000008103 glucose Substances 0.000 claims description 8
• 238000003780 insertion Methods 0.000 claims description 8
• 230000037431 insertion Effects 0.000 claims description 8
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 7
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 6
• 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 6
• 206010012735 Diarrhoea Diseases 0.000 claims description 6
• 206010022489 Insulin Resistance Diseases 0.000 claims description 6
• 108091006116 chimeric peptides Proteins 0.000 claims description 6
• 235000012000 cholesterol Nutrition 0.000 claims description 6
• 208000029742 colonic neoplasm Diseases 0.000 claims description 6
• 230000001419 dependent effect Effects 0.000 claims description 6
• 230000003345 hyperglycaemic effect Effects 0.000 claims description 6
• 150000002632 lipids Chemical class 0.000 claims description 6
• 229940068977 polysorbate 20 Drugs 0.000 claims description 6
• 108060003951 Immunoglobulin Proteins 0.000 claims description 5
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
• 230000001587 cholestatic effect Effects 0.000 claims description 5
• 230000000694 effects Effects 0.000 claims description 5
• 102000018358 immunoglobulin Human genes 0.000 claims description 5
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
• DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 4
• 206010069703 Bile acid malabsorption Diseases 0.000 claims description 4
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
• 230000015572 biosynthetic process Effects 0.000 claims description 4
• 206010012601 diabetes mellitus Diseases 0.000 claims description 4
• 230000001976 improved effect Effects 0.000 claims description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
• 208000001024 intrahepatic cholestasis Diseases 0.000 claims description 4
• 230000007872 intrahepatic cholestasis Effects 0.000 claims description 4
• 208000020816 lung neoplasm Diseases 0.000 claims description 4
• 208000030159 metabolic disease Diseases 0.000 claims description 4
• 230000000750 progressive effect Effects 0.000 claims description 4
• 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
• -1 trehalose anhydride Chemical class 0.000 claims description 4
• 229940074409 trehalose dihydrate Drugs 0.000 claims description 4
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
• 206010008635 Cholestasis Diseases 0.000 claims description 3
• 230000001965 increasing effect Effects 0.000 claims description 3
• 229920001184 polypeptide Polymers 0.000 claims description 3
• 150000003839 salts Chemical class 0.000 claims description 3
• TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical group C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 claims description 2
• 206010004593 Bile duct cancer Diseases 0.000 claims description 2
• 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 208000011231 Crohn disease Diseases 0.000 claims description 2
• 150000008574 D-amino acids Chemical class 0.000 claims description 2
• 102400000321 Glucagon Human genes 0.000 claims description 2
• 108060003199 Glucagon Proteins 0.000 claims description 2
• 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
• 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 102000004877 Insulin Human genes 0.000 claims description 2
• 108090001061 Insulin Proteins 0.000 claims description 2
• 150000008575 L-amino acids Chemical class 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 208000008589 Obesity Diseases 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 230000010757 Reduction Activity Effects 0.000 claims description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
• 206010072810 Vascular wall hypertrophy Diseases 0.000 claims description 2
• 230000005856 abnormality Effects 0.000 claims description 2
• 238000010521 absorption reaction Methods 0.000 claims description 2
• 230000003213 activating effect Effects 0.000 claims description 2
• 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
• 210000000013 bile duct Anatomy 0.000 claims description 2
• 230000036772 blood pressure Effects 0.000 claims description 2
• 210000004204 blood vessel Anatomy 0.000 claims description 2
• 230000037396 body weight Effects 0.000 claims description 2
• 230000007870 cholestasis Effects 0.000 claims description 2
• 231100000359 cholestasis Toxicity 0.000 claims description 2
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
• 229940079593 drug Drugs 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims description 2
• 208000009866 extrahepatic cholestasis Diseases 0.000 claims description 2
• 235000013861 fat-free Nutrition 0.000 claims description 2
• 208000001130 gallstones Diseases 0.000 claims description 2
• 208000004104 gestational diabetes Diseases 0.000 claims description 2
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
• 229960004666 glucagon Drugs 0.000 claims description 2
• 230000014101 glucose homeostasis Effects 0.000 claims description 2
• 230000010030 glucose lowering effect Effects 0.000 claims description 2
• 230000004153 glucose metabolism Effects 0.000 claims description 2
• 230000013632 homeostatic process Effects 0.000 claims description 2
• 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
• 201000008980 hyperinsulinism Diseases 0.000 claims description 2
• 208000036260 idiopathic disease Diseases 0.000 claims description 2
• 229940125396 insulin Drugs 0.000 claims description 2
• 239000007788 liquid Substances 0.000 claims description 2
• 201000007270 liver cancer Diseases 0.000 claims description 2
• 208000014018 liver neoplasm Diseases 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000037841 lung tumor Diseases 0.000 claims description 2
• 230000001404 mediated effect Effects 0.000 claims description 2
• 230000004060 metabolic process Effects 0.000 claims description 2
• 235000020824 obesity Nutrition 0.000 claims description 2
• 230000004203 pancreatic function Effects 0.000 claims description 2
• 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
• 208000023958 prostate neoplasm Diseases 0.000 claims description 2
• 210000000813 small intestine Anatomy 0.000 claims description 2
• 239000011780 sodium chloride Substances 0.000 claims description 2
• 125000006850 spacer group Chemical group 0.000 claims description 2
• 208000024891 symptom Diseases 0.000 claims description 2
• 238000003786 synthesis reaction Methods 0.000 claims description 2
• 150000003626 triacylglycerols Chemical class 0.000 claims description 2
• 230000004584 weight gain Effects 0.000 claims description 2
• 235000019786 weight gain Nutrition 0.000 claims description 2
• 108010091748 peptide A Proteins 0.000 claims 2
• 206010056375 Bile duct obstruction Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 206010056528 Neonatal cholestasis Diseases 0.000 claims 1
• 210000000941 bile Anatomy 0.000 claims 1
• 201000001883 cholelithiasis Diseases 0.000 claims 1
• 238000007906 compression Methods 0.000 claims 1
• 230000006835 compression Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 24
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 208000019298 familial intrahepatic cholestasis Diseases 0.000 description 1
• 208000007232 portal hypertension Diseases 0.000 description 1